Stadler WM - Search Results

1

A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.

Kochanny SE, Worden FP, Adkins DR, Lim DW, Bauman JE, Wagner SA, Brisson RJ, Karrison TG, Stadler WM, Vokes EE, Seiwert TY. Kochanny SE, et al. Among authors: stadler wm. Cancer. 2020 May 15;126(10):2146-2152. doi: 10.1002/cncr.32762. Epub 2020 Feb 19. Cancer. 2020. PMID: 32073648 Free PMC article. Clinical Trial.

2

Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a phase II study in metastatic renal-cell cancer.

Stadler WM, Vogelzang NJ, Vokes EE, Charette J, Whitman G. Stadler WM, et al. Cancer Chemother Pharmacol. 1992;31(3):213-6. doi: 10.1007/BF00685550. Cancer Chemother Pharmacol. 1992. PMID: 1464158 Clinical Trial.

3

A phase II study of subcutaneous recombinant human interleukin-4 in metastatic renal cell carcinoma.

Stadler WM, Rybak ME, Vogelzang NJ. Stadler WM, et al. Cancer. 1995 Nov 1;76(9):1629-33. doi: 10.1002/1097-0142(19951101)76:9<1629::aid-cncr2820760920>3.0.co;2-q. Cancer. 1995. PMID: 8635068 Clinical Trial.

4

Metastatic bladder cancer: advances in treatment.

Stadler WM, Kuzel TM, Raghavan D, Levine E, Vogelzang NJ, Roth B, Dorr FA. Stadler WM, et al. Eur J Cancer. 1997 Jan;33 Suppl 1:S23-6. doi: 10.1016/s0959-8049(96)00337-1. Eur J Cancer. 1997. PMID: 9166096 Review.

5

Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trial.

Rini BI, Stadler WM, Spielberger RT, Ratain MJ, Vogelzang NJ. Rini BI, et al. Among authors: stadler wm. Cancer. 1998 Apr 1;82(7):1352-8. doi: 10.1002/(sici)1097-0142(19980401)82:7<1352::aid-cncr19>3.0.co;2-5. Cancer. 1998. PMID: 9529028 Clinical Trial.

6

Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.

Vogelzang NJ, Mani S, Schilsky RL, Ansari RH, Taber D, Rhinehart SN, Garcia JC, Meyer SC, Mick R, Brockstein BE, Stadler WM, Ratain MJ, Vokes EE. Vogelzang NJ, et al. Among authors: stadler wm. Clin Cancer Res. 1998 Apr;4(4):929-34. Clin Cancer Res. 1998. PMID: 9563886 Clinical Trial.

7

Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study.

Stadler WM, Vogelzang NJ, Amato R, Sosman J, Taber D, Liebowitz D, Vokes EE. Stadler WM, et al. J Clin Oncol. 2000 Jan;18(2):371-5. doi: 10.1200/JCO.2000.18.2.371. J Clin Oncol. 2000. PMID: 10637252 Clinical Trial.

8

Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.

Ryan CW, Vogelzang NJ, Dumas MC, Kuzel T, Stadler WM. Ryan CW, et al. Among authors: stadler wm. Cancer. 2000 Mar 15;88(6):1317-24. Cancer. 2000. PMID: 10717612 Clinical Trial.

9

Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea.

Innocenti F, Stadler WM, Iyer L, Ramírez J, Vokes EE, Ratain MJ. Innocenti F, et al. Among authors: stadler wm. Clin Cancer Res. 2000 Sep;6(9):3400-5. Clin Cancer Res. 2000. PMID: 10999721

10

Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers.

Kim HL, Vander Griend DJ, Yang X, Benson DA, Dubauskas Z, Yoshida BA, Chekmareva MA, Ichikawa Y, Sokoloff MH, Zhan P, Karrison T, Lin A, Stadler WM, Ichikawa T, Rubin MA, Rinker-Schaeffer CW. Kim HL, et al. Among authors: stadler wm. Cancer Res. 2001 Apr 1;61(7):2833-7. Cancer Res. 2001. PMID: 11306453

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

338 results

Search Page